Short Interest in Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) Expands By 90.3%

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) was the target of a significant growth in short interest in the month of August. As of August 31st, there was short interest totaling 27,111 shares, a growth of 90.3% from the August 15th total of 14,245 shares. Based on an average daily volume of 331,733 shares, the short-interest ratio is currently 0.1 days. Approximately 0.0% of the shares of the company are sold short.

Analyst Upgrades and Downgrades

A number of brokerages have commented on CHGCY. The Goldman Sachs Group upgraded Chugai Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Monday, June 15th. Zacks Research upgraded Chugai Pharmaceutical to a “hold” rating in a research note on Friday, May 29th. UBS Group lowered shares of Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 6th. Finally, Nomura upgraded shares of Chugai Pharmaceutical to a “hold” rating in a research note on Tuesday, September 1st. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, Chugai Pharmaceutical has an average rating of “Moderate Buy”.

Chugai Pharmaceutical Stock Performance

CHGCY opened at $20.75 on Tuesday. The stock has a market cap of $68.30 billion, a price-to-earnings ratio of 22.55 and a beta of 0.59. The firm’s fifty day moving average is $21.83 and its 200 day moving average is $24.67. Chugai Pharmaceutical has a fifty-two week low of $20.00 and a fifty-two week high of $34.84.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last issued its quarterly earnings results on Friday, July 24th. The company reported $0.22 earnings per share (EPS) for the quarter. The business had revenue of $2.14 billion during the quarter, compared to analyst estimates of $2.38 billion. Chugai Pharmaceutical had a return on equity of 23.76% and a net margin of 35.09%. On average, equities research analysts predict that Chugai Pharmaceutical will post 0.96 earnings per share for the current year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd. is a Japan-based research-driven pharmaceutical company headquartered in Tokyo. Founded in 1925, the company focuses on discovering, developing, manufacturing and commercializing prescription medicines, with an emphasis on biotechnology and innovative therapies for serious and unmet medical needs.

Chugai’s principal therapeutic areas include oncology, hematology, immunology, neuroscience and renal diseases. Its products include Actemra (known as RoActemra in some markets) for inflammatory and immune-related conditions, Hemlibra for hemophilia A, and Alecensa for certain forms of lung cancer.